On this episode of EyeCan, we are excited to introduce our listeners to Dr. Netan Choudhry, co-founder and medical director of the Vitreous Retina Macula Specialists of Toronto, a premier academic retina practice.
Dr. Choudhry is an internationally recognized Vitreoretinal Surgeon with affiliations at both the University of Toronto and Harvard Medical School, and Ophthalmology Lead at the Cleveland Clinic Canada. He is universally recognized as a thought leader in retinal imaging and the diagnosis and treatment of rare disorders of the retina and vitreous.
Dr. Choudhry was one of the first to pioneer OCT imaging of the peripheral retina and is actively developing novel devices for imaging the retina and vitreous using non-invasive technology. He has published in the world’s most read/indexed journals including: The New England Journal of Medicine, the Lancet, Ophthalmology and the Retina Journal. Dr. Choudhry has authored several book chapters in retinal imaging.
Dr. Choudhry’s innovative work in the field of retina has also been published on the covers of numerous journals further earning him the distinction of a pioneer in retinal imaging. His current research focus continues to be in the integration of novel retinal imaging technologies with Artificial Intelligence and imaging biomarkers.
He is an elected member of the Retina Society and Macula Society. He has been a member of the board of directors at the American Society of Retina Specialists, Canadian Retina Society and currently sits on the Board of Directors of the Foundation Fighting Blindness Canada.
With your hosts, Dr. Guillermo Rocha, Dr. Setareh Ziai, Dr. Mona Dagher, and Dr. Hady Saheb.
Written and Directed by Kim Tytler.
Produced by John Allaire of Allaire Strategic Works.
The EyeCan Podcast is made possible by support from Bayer.
With your hosts, Dr. Guillermo Rocha, Dr. Setareh Ziai, Dr. Mona Dagher, and Dr. Hady Saheb.
Written and Directed by Kim Tytler.
Produced by John Allaire of Allaire Strategic Works.
The EyeCan Podcast is made possible by support from Bayer.